Meeting
2020 ASCO Virtual Scientific Program
Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).
Authors
Jason Alan Chesney
James Graham Brown Cancer Center, University of Louisville, Louisville, KY
Jason Alan Chesney , Igor Puzanov , Frances A. Collichio , Mohammed M. Milhem , Axel Hauschild , Min Yi , Sumita Bhatta , Rubina Ismail , Claus Garbe , Parminder Singh , Janice M. Mehnert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01740297
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10029)
DOI
10.1200/JCO.2020.38.15_suppl.10029
Abstract #
10029
Poster Bd #
378
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI).
First Author: Charlene Mantia
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis
Poster
2022 ASCO Annual Meeting
Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma.
First Author: Olivier Jules van Not
Poster
2022 ASCO Annual Meeting
Thromboembolism (TE) and association with survival in patients (pts) with melanoma receiving chemo– or immunotherapy.
First Author: Tamara A. Sussman